Trending

GSK

GSK enters PARP space with TESARO acquisition

GSK enters PARP space with TESARO acquisition

GSK has announced that it will acquire US-based oncology specialist TESARO for $5.1 billion, gaining access to its

X

GSK enters PARP space with TESARO acquisition

https://pharmaphorum.com/news/gsk-enters-parp-space-with-tesaro-acquisition/

GSK and Sanofi to Present the Opening Keynote Sessions

GSK and Sanofi to Present the Opening Keynote Sessions

Cold Chain Distribution Conference

X

GSK and Sanofi to Present the Opening Keynote Sessions

https://pharmaphorum.com/partner-content/gsk-and-sanofi-to-present-the-opening-keynote-sessions/

Tafenoquine – single shot malaria cure endorsed by the FDA advisers

Tafenoquine – single shot malaria cure endorsed by the FDA advisers

The US Food and Drugs Administration Advisory Committee has endorsed tafenoquine, a single-dose drug from the GSK pipeline

X

Tafenoquine – single shot malaria cure endorsed by the FDA advisers

https://pharmaphorum.com/news/tafenoquine-single-shot-malaria-cure-endorsed-by-the-fda/

GSK collaborates on AI-driven drug design with Cloud Pharmaceuticals

GSK collaborates on AI-driven drug design with Cloud Pharmaceuticals

GlaxoSmithKline (GSK) is set to apply artificial intelligence (AI) technology to improve its drug discovery efforts through a

X

GSK collaborates on AI-driven drug design with Cloud Pharmaceuticals

https://pharmaphorum.com/news/gsk-ai-drug-design-cloud-pharmaceuticals/

GSK strengthens core prescription business with Sin hire

In a drive to boost its search for innovative products worldwide, GlaxoSmithKline (GSK) has hired Kevin Sin from

X

GSK strengthens core prescription business with Sin hire

https://pharmaphorum.com/news/gsk-strengthens-core-prescription-business-with-sin-hire/

GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship

GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship

The chief executive of GlaxoSmithKline has welcomed the breakthrough in talks between the UK and EU27 countries on a transition or ‘implementation’ period.

X

GSK welcomes Brexit transition deal, but wants more ‘precision’ on final relationship

https://pharmaphorum.com/news/gsk-welcomes-brexit-transition-deal-big-questions-medicines-remain/

GSK’s former chief Witty makes surprise move to ‘the dark side’

GSK’s former chief Witty makes surprise move to ‘the dark side’

GlaxoSmithKline’s former chief executive Andrew Witty was yesterday announced as the new CEO of Optum – a US payer organisation which includes pharmacy benefits manager OptumRx.

X

GSK’s former chief Witty makes surprise move to ‘the dark side’

https://pharmaphorum.com/news/gsks-former-chief-witty-makes-surprise-move-dark-side/

Advair reprieve gives GSK breathing space

Advair reprieve gives GSK breathing space

GlaxoSmithKline looks set to have another year without US generic competition to its respiratory blockbuster Advair, after the

X

Advair reprieve gives GSK breathing space

https://pharmaphorum.com/news/advair-reprieve-gives-gsk-breathing-space/

Rumours of $1.65bn GSK bid for respiratory partners Vectura

Rumours of $1.65bn GSK bid for respiratory partners Vectura

GlaxoSmithKline could be poised to acquire its respiratory partner, UK biotech Vectura, for $1.65bn.

X

Rumours of $1.65bn GSK bid for respiratory partners Vectura

https://pharmaphorum.com/news/rumours-1-65bn-gsk-bid-respiratory-partners-vectura/

1 2 3 4 5

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com